# RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct07808138/  
OnCo record `nct07808138` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in lung cancer, run by The Netherlands Cancer Institute, not yet recruiting.

## Summary

RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer is a phase 2, interventional study registered as NCT07808138 by The Netherlands Cancer Institute, with a registry enrolment figure of 30 participants, started 2026-11 and due to reach its primary completion in 2029-12-01. Interventions recorded: Cemiplimab 350 mg IV. Conditions listed: Non Small Cell Lung Cancer; Immunotherapy. Primary outcome: Recurrence free survival (RFS) as per RECIST 1.1. Lung eligibility wording from the registry: "tumor diameter ≤ 3 cm) NSCLC according to the 9th AJCC/UICC staging classification (30)". Sites: Netherlands. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Also known as: RADICAL-IO
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07808138
- Phase: 2
- Setting: RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer
- Sponsor: The Netherlands Cancer Institute
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07808138: https://clinicaltrials.gov/study/NCT07808138

## Connected records

- cancers: [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07808138.json